Exenatide once weekly in type 2 diabetes mellitus

Bibliography

• National Diabetes Statistics, 2007. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics [Last accessed 25 January 2011]
   Google Scholar
• Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008;134:1137-47
   PubMed Web of Science ®Google Scholar
• Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002;146:863-9
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least three years. Curr Med Res Opin 2008;24:275-86
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals, Eli Lilly, and Co. Byetta package insert. Sept 2010
   Google Scholar
• Novo Nordisk. Victoza package insert. Jan 2010
   Google Scholar
• Garber A, Henry R, Ratner R, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   PubMed Web of Science ®Google Scholar
• David Joffe. Liraglutide: a once daily human glucagon like peptide-1 analogue for type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:1326-36
   Google Scholar
• Bjerre Knudsen L, Madsen LW, Andersen S, Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86
   PubMed Web of Science ®Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86
   PubMed Web of Science ®Google Scholar
• Gm Keating. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112
   Google Scholar
• Amylin Pharmaceuticals. Januvia (sitagliptin) prescribing information. Jan 2011
   Google Scholar
• Merck Pharmaceuticals. Onglyza (saxagliptin) prescribing information. revised and published Feb 2011
   Google Scholar
• Fact Sheet Medisorb® Microspheres Technology, January 2009. Available from: http://www.alkermes.com/media/42408/general%20medisorb%20techonology%20fact%20sheet%20jan%202009%20-%20011409%20pdf [Last accessed 20 November 2010]
   Google Scholar
• Chen YE, Drucker DJ. Tissue-specific expressions of unique mRNAs that encode proglucagon-derived peptides or exendin-4 in the lizard. J Biol Chem 1997;272:4108-15
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals. Byetta (exenatide) injection prescribing information. Published Sept 2010
   Google Scholar
• Kim D, MacConell L, Zhuang D, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
   PubMed Web of Science ®Google Scholar
• Gardner DG, Shoback D. Greenspan's basic and clinical endocrinology. 8th edition. McGraw-Hill; 2007. p. 664-5, USA
   Google Scholar
• Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Nasu R, Yamamura A, Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009;56:951-62
   PubMed Web of Science ®Google Scholar
• Copley K, McCowen K, Hiles R, Investigation of exenatide elimination and its in vivo and in vitro degredation. Curr Drug Metab 2006;7:367-74
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Kothare PA, Park S, Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, ; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, ; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 22 Mar 2011 [Epub ahead of print]
   Google Scholar
• Amylin Pharmaceuticals. DURATION-4: study results: BYDUREON efficacy and tolerability profile extended to monotherapy treatment. Press release. Available from: http://investors.amylin.com/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1438147&highlight=) [Last accessed 24 January 2011]
   Google Scholar
• Fineman MS, Biscak TA, Shen LZ, Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7
   PubMed Web of Science ®Google Scholar
• Buse JB, Montanya E, Sesti G, The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head-to-head comparison [abstract 857-P]. Presented at the 46th Annual Meeting of the European Association for the Study of Diabetes, 20 – 24 September 2010, Stockholm, Sweden
   Google Scholar
• Investor Update. 18 June 2010. Available from: http://www.roche.com/investors/ir_update [Last accessed 6 March 2011]
   Google Scholar
• Blevins T, Pullman J, Malloy J, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 9 Feb 2011 [Epub ahead of print]
   Google Scholar
• Raskin P, Mohan A. Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial). Expert Opin Pharmacother 2010;11:2269-71
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Dore D, Wenton M, Incidence and relative incidence of medical record confirmed acute pancreatitis: exenatide initiators compared to other antidiabetic drug initiators [abstract 543-P]. Presented at the American Diabetes Association 70th Scientific Sessions, 25 – 29 June 2010, Orlando, Florida, USA
   Google Scholar
• Wenten M, Gaebler J, Hussein M, A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other antidiabetic medication: a follow up study [abstract 596-P]. Presented at the American Diabetes Association 70th Scientific Sessions, 25 – 29 June 2010, Orlando, Florida, USA
   Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005
   Google Scholar
• Linnebjerg H, Seger M, Kothare P, The effects of exenatide on QTc interval in healthy subjects [abstract 597-P]. Presented at the American Diabetes Association 70th Scientific Sessions, 25 – 29 June 2010, Orlando, Florida, USA
   Google Scholar